Jonathan Chang
Stock Analyst at Leerink Partners
(0.65)
# 3,702
Out of 4,829 analysts
86
Total ratings
30.14%
Success rate
-19.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Upgrades: Outperform | $27 | $19.36 | +39.46% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $28.40 | +160.56% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $3.41 | +222.58% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $17.38 | +193.44% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $6.02 | +1,146.88% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $7.71 | +340.99% | 9 | Dec 7, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $8.34 | +499.52% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $40.42 | -25.78% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.43 | +739.16% | 8 | Aug 9, 2022 | |
| MRSN Mersana Therapeutics | Maintains: Outperform | $13 → $14 | $0.32 | +4,290.09% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $4.26 | +511.05% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $29.24 | +224.90% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.29 | +925.29% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $5.76 | +386.11% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $8.33 | +536.25% | 7 | Aug 5, 2021 |
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $19.36
Upside: +39.46%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $28.40
Upside: +160.56%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $3.41
Upside: +222.58%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $17.38
Upside: +193.44%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $6.02
Upside: +1,146.88%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $7.71
Upside: +340.99%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $8.34
Upside: +499.52%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $40.42
Upside: -25.78%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.43
Upside: +739.16%
Mersana Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $0.32
Upside: +4,290.09%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $4.26
Upside: +511.05%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $29.24
Upside: +224.90%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.29
Upside: +925.29%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $5.76
Upside: +386.11%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $8.33
Upside: +536.25%